Happy Friday!
Or… maybe not so happy for the president Donald Trump and his Wife Melania who have both tested positive for COVID 19!
The president’s doctor has issued a statement saying that the couple are fine and expects Trump to carry out his duties whilst in quarantine at the WhiteHouse.
Across Markets…
This Afternoon, the Australian sharemarket slumped to its worst weekly performance since April after a late Friday sell-off sparked by US President Donald Trump’s shock COVID-19 diagnosis.
The news rattled global markets, driving the S&P/ASX200 Index down 81.4 points, or 1.4 per cent, to 5791.5 points on Friday and pushing the benchmark to a 2.9 per cent loss for the week – the worst performance since the week ended April 24.
Banks and miners accounted for the bulk of the losses. BHP fell 3.2 per cent, Westpac tumbled 2 per cent and Telstra lost 1.1 per cent.
Gold stocks gained as the precious metal jumped from $US1890 an ounce before the news to $US1907 an ounce late on Friday.
Evolution Mining rose 0.9 per cent, Newcrest Mining gained 0.8 per cent, St Barbara rose 1 per cent, and Saracen added 1 per cent.
Source: AFR
Mesoblast (ASX:MSB) shares have plunged by a third after the US Food and Drug Administration asked the biotech company to conduct another study of its stem cell treatment for children with a complication from bone marrow transplants.
Given that there’s no treatment available on the market for steroid-refractory acute graft-versus-host disease in children under 12 and that the condition can be life-threatening, Mesoblast says it plans to urgently request a meeting with the FDA to discuss a potential accelerated approval of Ryoncil with a post-approval condition for an additional study.
The meeting is expected to take place within 30 days.
An extended delay would be disastrous for Mesoblast, which lost $108m last year ramping up industrial-scale manufacturing of Ryoncil (remestemcel-L) and putting a sales team in place.
“We are working tirelessly to bring remestemcel-L to patients with life threatening inflammatory conditions, including SR-aGVHD and COVID-19 ARDS,” Mesoblast chief executive Dr Silviu Itescu said.
Source: Small Caps
Across Asia, the Tokyo Stock Exchange (TSE) resumed normal trading on Friday, with the main index holding steady a day after the worst-ever outage brought the world’s third-largest equity market to a standstill.
The glitch was the result of a hardware problem at the bourse’s “Arrowhead” trading system, and a subsequent failure to switch to a back-up. It caused the first full-day suspension since the exchange moved to all-electronic trading in 1999.
Market participants expressed some relief that the problem was hardware-related rather than a cyber attack, but cautioned about a potential longer-term impact given the hit to the Tokyo market’s reputation.
“For now, there’s relief that trade was able to resume,” said Masahiro Ichikawa, senior strategist at Sumitomo Mitsui DS Asset Management.
Source: Reuters
Sector: Consumer Discretionary
Year: 2019
Deal Type: Placement
Raise Amount: $2.2m
Price Change: $0.052 -3.70%
Sector: Consumer Discretionary
Year: 2018, 2019
Deal Type: Seed, Bridging and IPO
Raise Amount: $10m
Price Change: $0.16 -3.12%
Sector: Technology
Year: 2018
Deal Type: Seed and IPO
Raise Amount: $10m
Price Change: $0.13 +4.00%
Sector: Mining
Year: 2017
Deal Type: Seed & IPO
Raise Amount: $5m
Price Change: $0.17 -2.88%
Sector: Mining
Year: 2017
Deal Type: IPO & Placement
Raise Amount: $6m
Price Change: $0.060 -4.76%
Sector: Healthcare Equipment and Services
Year: 2016
Deal Type: IPO
Raise Amount: $8m
Price Change: $0.049 Unchanged
Sector: Materials
Year: 2016
Deal Type: IPO
Raise Amount: $9m
Price Change: $0.030 +20.00%
Sector: Biotechnology
Year: 2015, 2017, 2018
Deal Type: Placements & IPO
Raise Amount: $5m
Price Change: $2.66 -6.99%
Sector: Media an Entertainment
Year: 2016
Deal Type: Reverse Takeover
Raise Amount: $4m
Price Change: $0.031 -3.13%
Sector: mining
Year: 2018, 2019, 2020
Deal Type: Placements & Rights Offer
Raise Amount: $1.5m
Price Change: $0.009 -25.00%
Sector: Discretionary
Year: 2020
Deal Type: Placement
Raise Amount: $1.3M
Price Change: $0.0060 Unchanged
Sector: Hemp & CBD
Year: 2020
Deal Type: Pre IPO
Raise Amount: $2.5m
Sector: Psychedelic assisted Therapy
Year: 2020
Deal Type: Pre IPO
Raise Amount: $1.5m
Price Change: CAD $0.065 -13.33%
Sector: Mining
Year: 2020
Deal Type: Placement
Raise Amount: $333k
Sector: Gaming & Digital Advertising
Year: 2020
Deal Type: Placement
Raise Amount: $1.25m
Sector: Mining (Gold)
Year: 2020
Deal Type: Placement
Raise Amount: $982k
Price Change: $0.010 Unchanged
Sector: Mining (Gold/Silver)
Year: 2020
Deal Type: Placement
Raise Amount: $2.3m
Price Change: $0.014 Unchanged
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
